84 related articles for article (PubMed ID: 21475617)
21. Racial differences in patterns of treatment among men diagnosed with de novo advanced prostate cancer: A SEER-Medicare investigation.
Beebe-Dimmer JL; Ruterbusch JJ; Cooney KA; Bolton A; Schwartz K; Schwartz AG; Heath E
Cancer Med; 2019 Jun; 8(6):3325-3335. PubMed ID: 31094098
[TBL] [Abstract][Full Text] [Related]
22. Flexible boosting of accelerated failure time models.
Schmid M; Hothorn T
BMC Bioinformatics; 2008 Jun; 9():269. PubMed ID: 18538026
[TBL] [Abstract][Full Text] [Related]
23. A flexible parametric approach to examining spatial variation in relative survival.
Cramb SM; Mengersen KL; Lambert PC; Ryan LM; Baade PD
Stat Med; 2016 Dec; 35(29):5448-5463. PubMed ID: 27503837
[TBL] [Abstract][Full Text] [Related]
24. Spatially-explicit survival modeling with discrete grouping of cancer predictors.
Onicescu G; Lawson AB; Zhang J; Gebregziabher M; Wallace K; Eberth JM
Spat Spatiotemporal Epidemiol; 2019 Jun; 29():139-148. PubMed ID: 31128623
[TBL] [Abstract][Full Text] [Related]
25. Bayesian area-age-period-cohort model with carcinogenesis age effects in estimating cancer mortality.
Xu Z; Hertzberg VS
Cancer Epidemiol; 2013 Oct; 37(5):593-600. PubMed ID: 23891684
[TBL] [Abstract][Full Text] [Related]
26. Bayesian variable selection in the accelerated failure time model with an application to the surveillance, epidemiology, and end results breast cancer data.
Zhang Z; Sinha S; Maiti T; Shipp E
Stat Methods Med Res; 2018 Apr; 27(4):971-990. PubMed ID: 28034170
[TBL] [Abstract][Full Text] [Related]
27. Parametric models for accelerated and long-term survival: a comment on proportional hazards.
Frankel P; Longmate J
Stat Med; 2002 Nov; 21(21):3279-89. PubMed ID: 12375304
[TBL] [Abstract][Full Text] [Related]
28. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
29. Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics.
Cronin KA; Lake AJ; Scott S; Sherman RL; Noone AM; Howlader N; Henley SJ; Anderson RN; Firth AU; Ma J; Kohler BA; Jemal A
Cancer; 2018 Jul; 124(13):2785-2800. PubMed ID: 29786848
[TBL] [Abstract][Full Text] [Related]
30. Semiparametric Accelerated Failure Time Partial Linear Model and Its Application to Breast Cancer.
Zou Y; Zhang J; Qin G
Comput Stat Data Anal; 2011 Mar; 55(3):1479-1487. PubMed ID: 21499529
[TBL] [Abstract][Full Text] [Related]
31. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
[TBL] [Abstract][Full Text] [Related]
32. Parametric survival models for predicting the benefit of adjuvant chemoradiotherapy in gallbladder cancer.
Wang SJ; Kalpathy-Cramer J; Kim JS; Fuller CD; Thomas CR
AMIA Annu Symp Proc; 2010 Nov; 2010():847-51. PubMed ID: 21347098
[TBL] [Abstract][Full Text] [Related]
33. Effect of young age on prostate cancer survival: a population-based assessment (United States).
Merrill RM; Bird JS
Cancer Causes Control; 2002 Jun; 13(5):435-43. PubMed ID: 12146848
[TBL] [Abstract][Full Text] [Related]
34. Racial/ethnic disparities in de novo metastases sites and survival outcomes for patients with primary breast, colorectal, and prostate cancer.
Akinyemiju T; Sakhuja S; Waterbor J; Pisu M; Altekruse SF
Cancer Med; 2018 Apr; 7(4):1183-1193. PubMed ID: 29479835
[TBL] [Abstract][Full Text] [Related]
35. Accelerated failure-time model with weighted least-squares estimation: application on survival of HIV positives.
Mustefa YA; Chen DG
Arch Public Health; 2021 May; 79(1):88. PubMed ID: 34059125
[TBL] [Abstract][Full Text] [Related]
36. Socioeconomic status and prostate cancer incidence and mortality rates among the diverse population of California.
Cheng I; Witte JS; McClure LA; Shema SJ; Cockburn MG; John EM; Clarke CA
Cancer Causes Control; 2009 Oct; 20(8):1431-40. PubMed ID: 19526319
[TBL] [Abstract][Full Text] [Related]
37. Explaining the race difference in prostate cancer stage at diagnosis.
Jones BA; Liu WL; Araujo AB; Kasl SV; Silvera SN; Soler-Vilá H; Curnen MG; Dubrow R
Cancer Epidemiol Biomarkers Prev; 2008 Oct; 17(10):2825-34. PubMed ID: 18829446
[TBL] [Abstract][Full Text] [Related]
38. Prior choice in discrete latent modeling of spatially referenced cancer survival.
Lawson AB; Choi J; Zhang J
Stat Methods Med Res; 2014 Apr; 23(2):183-200. PubMed ID: 22556109
[TBL] [Abstract][Full Text] [Related]
39. Spatially explicit survival modeling for small area cancer data.
Onicescu G; Lawson A; Zhang J; Gebregziabher M; Wallace K; Eberth JM
J Appl Stat; 2018; 45(3):568-585. PubMed ID: 30906096
[TBL] [Abstract][Full Text] [Related]
40. Descriptive characteristics of prostate cancer in patients with a history of primary male breast cancer - a SEER analysis.
Abhyankar N; Hoskins KF; Abern MR; Calip GS
BMC Cancer; 2017 Sep; 17(1):659. PubMed ID: 28946846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
